(Q44704637)

English

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis

scientific article published in November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

author name string

Arvind Agrawal

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Maureen C Sautter

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Nigel P Jones

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

2754-2764

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Similar risks of nephropathy in patients with type I or type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A risk-benefit assessment of metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980331-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80331-4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44704637&oldid=2098835344"